Caris Life Sciences Inc: Nasdaq AI‑driven precision‑medicine company trades around $31, market cap $8.3 billion, no new earnings or corporate news as of 30 Sept 2025.

Caris Life Sciences reports strong financial performance, including an 81% revenue increase, and strategic moves to expand its global footprint and diversify its portfolio.

Caris Life Sciences Inc’s stock price has been on a rollercoaster ride on Nasdaq, reflecting the company’s challenges and opportunities in the competitive biotech landscape.

Caris Life Sciences Inc. is a leading player in the AI-driven healthcare revolution, poised to capitalize on the growing demand for AI-powered health tech solutions.